Published in Cardiovasc Res on March 28, 2008
Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. Circulation (2010) 1.49
Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapy. Eur Heart J (2012) 1.44
The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective. Cardiovasc Res (2009) 1.36
Beta3 integrin-mediated ubiquitination activates survival signaling during myocardial hypertrophy. FASEB J (2009) 1.19
Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol (2010) 1.17
Myocardial knockdown of mRNA-stabilizing protein HuR attenuates post-MI inflammatory response and left ventricular dysfunction in IL-10-null mice. FASEB J (2010) 1.16
The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. Cardiovasc Res (2009) 1.16
Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice. Circ Res (2012) 1.15
A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome. Am J Physiol Heart Circ Physiol (2008) 1.15
Proteasomal and lysosomal protein degradation and heart disease. J Mol Cell Cardiol (2013) 1.12
Back to your heart: ubiquitin proteasome system-regulated signal transduction. J Mol Cell Cardiol (2011) 1.05
The role of the proteasome in heart disease. Biochim Biophys Acta (2010) 0.99
The ubiquitin proteasome system in human cardiomyopathies and heart failure. Am J Physiol Heart Circ Physiol (2013) 0.99
Left ventricular global transcriptional profiling in human end-stage dilated cardiomyopathy. Genomics (2009) 0.98
Primary proteasome inhibition results in cardiac dysfunction. Eur J Heart Fail (2013) 0.96
Network topology reveals key cardiovascular disease genes. PLoS One (2013) 0.96
Role of various proteases in cardiac remodeling and progression of heart failure. Heart Fail Rev (2012) 0.95
Autophagy and the ubiquitin-proteasome system in cardiac dysfunction. Panminerva Med (2010) 0.92
Regulation of posttranscriptional modification as a possible therapeutic approach for retinal neuroprotection. J Ophthalmol (2010) 0.87
Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis. J Clin Invest (2016) 0.86
Resveratrol protects against doxorubicin-induced cardiotoxicity in aged hearts through the SIRT1-USP7 axis. J Physiol (2015) 0.85
Altered ubiquitin-proteasome signaling in right ventricular hypertrophy and failure. Am J Physiol Heart Circ Physiol (2013) 0.85
Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. Physiol Genomics (2013) 0.83
ZASP interacts with the mechanosensing protein Ankrd2 and p53 in the signalling network of striated muscle. PLoS One (2014) 0.82
Influence of p53 in the transition of myotrophin-induced cardiac hypertrophy to heart failure. Cardiovasc Res (2010) 0.81
Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity. Case Rep Cardiol (2016) 0.80
Z-disc transcriptional coupling, sarcomeroptosis and mechanoptosis [corrected]. Cell Biochem Biophys (2013) 0.79
Anti-Fas gene therapy prevents doxorubicin-induced acute cardiotoxicity through mechanisms independent of apoptosis. Am J Pathol (2009) 0.79
Autophagic vacuoles in cardiomyocytes of dilated cardiomyopathy with initially decompensated heart failure predict improved prognosis. Autophagy (2016) 0.78
Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy. Front Physiol (2014) 0.78
Cardiac deficiency of single cytochrome oxidase assembly factor scox induces p53-dependent apoptosis in a Drosophila cardiomyopathy model. Hum Mol Genet (2015) 0.76
Proteasome inhibitors attenuated cholesterol-induced cardiac hypertrophy in H9c2 cells. BMB Rep (2016) 0.75
Ubiquitin and ubiquitin-like proteins in cardiac disease and protection. Curr Drug Targets (2015) 0.75
Bortezomib-induced Severe Congestive Heart Failure. Cardiol Res (2010) 0.75
Metabolic Origins of Heart Failure. JACC Basic Transl Sci (2017) 0.75
Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med (2006) 8.98
Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J (2004) 7.84
Truncations of titin causing dilated cardiomyopathy. N Engl J Med (2012) 6.07
Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem Biol (2002) 3.43
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41
Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation (2011) 3.18
Design and use of conditional MHC class I ligands. Nat Med (2006) 3.01
Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell (2005) 2.76
Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide substrate. J Biol Chem (2004) 2.75
Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. Circ Res (2002) 2.73
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure (2006) 2.56
Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc (2006) 2.47
Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular arrhythmias in a rat chronic ischemic heart failure model. Circulation (2007) 2.24
Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J (2004) 2.23
A population study of endomyocardial fibrosis in a rural area of Mozambique. N Engl J Med (2008) 2.10
Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation. Proc Natl Acad Sci U S A (2004) 2.09
Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity (2013) 2.05
OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis. Cell (2013) 2.05
Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell (2007) 2.01
Endonuclease G is a novel determinant of cardiac hypertrophy and mitochondrial function. Nature (2011) 1.98
Long-term outcomes after autograft versus homograft aortic root replacement in adults with aortic valve disease: a randomised controlled trial. Lancet (2010) 1.95
Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins. Mol Cell Biol (2004) 1.86
Endothelium-dependent regulation of the mechanical properties of aortic valve cusps. J Am Coll Cardiol (2009) 1.85
Revisiting the pathogenesis of rheumatic fever and carditis. Nat Rev Cardiol (2013) 1.84
Chemical synthesis of ubiquitin, ubiquitin-based probes, and diubiquitin. Angew Chem Int Ed Engl (2010) 1.83
Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol (2011) 1.81
Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A (2010) 1.80
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods (2005) 1.78
Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy. Eur Heart J (2006) 1.78
Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci U S A (2008) 1.77
The cardiac valve interstitial cell. Int J Biochem Cell Biol (2003) 1.76
Role of human valve interstitial cells in valve calcification and their response to atorvastatin. Circulation (2006) 1.75
NF-kappaB suppression by the deubiquitinating enzyme Cezanne: a novel negative feedback loop in pro-inflammatory signaling. J Biol Chem (2008) 1.74
Late outcomes following freestyle versus homograft aortic root replacement: results from a prospective randomized trial. J Am Coll Cardiol (2010) 1.72
Clinical, molecular, and genomic changes in response to a left ventricular assist device. J Am Coll Cardiol (2011) 1.69
A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J (2011) 1.67
Cellular and molecular mechanisms of thoracic aortic aneurysms. Nat Rev Cardiol (2009) 1.65
The Ross procedure: a systematic review and meta-analysis. Circulation (2008) 1.65
Myocardial sympathetic innervation and long-term left ventricular mechanical unloading. JACC Cardiovasc Imaging (2010) 1.61
The differential modulation of USP activity by internal regulatory domains, interactors and eight ubiquitin chain types. Chem Biol (2011) 1.58
The A20 gene protects kidneys from ischaemia/reperfusion injury by suppressing pro-inflammatory activation. J Mol Med (Berl) (2008) 1.58
Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Tissue Eng (2006) 1.57
Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase. Mol Cell (2011) 1.56
An ankyrin-repeat ubiquitin-binding domain determines TRABID's specificity for atypical ubiquitin chains. Nat Struct Mol Biol (2011) 1.55
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood (2007) 1.54
A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem Biol (2006) 1.54
Establishing pediatric cardiovascular services in the developing world: a wake-up call. Circulation (2007) 1.54
Autoimmunity to vimentin potentiates graft vasculopathy in murine cardiac allografts. Transplantation (2010) 1.50
Collagen synthesis by mesenchymal stem cells and aortic valve interstitial cells in response to mechanical stretch. Cardiovasc Res (2006) 1.47
Role of nuclear factor kappaB in cardiovascular health and disease. Clin Sci (Lond) (2010) 1.44
The deubiquitinating enzyme UCH-L3 regulates the apical membrane recycling of the epithelial sodium channel. J Biol Chem (2007) 1.43
Multigene adenoviral therapy for the attenuation of ischemia-reperfusion injury after preservation for cardiac transplantation. J Thorac Cardiovasc Surg (2003) 1.43
Activation of Nrf2 in endothelial cells protects arteries from exhibiting a proinflammatory state. Arterioscler Thromb Vasc Biol (2009) 1.43
Bridge to recovery: what remains to be discovered? Cardiol Clin (2011) 1.42
Development of an in vivo ischemia-reperfusion model in heterotopically transplanted rat hearts. Transplantation (2002) 1.40
ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med (2002) 1.39
Preserved homograft function 32 years after surgery in a young patient. J Thorac Cardiovasc Surg (2010) 1.38
Dynamics and mediators of acute graft attrition after myoblast transplantation to the heart. FASEB J (2004) 1.38
Single fibers of skeletal muscle as a novel graft for cell transplantation to the heart. J Thorac Cardiovasc Surg (2002) 1.37
Localization and pattern of expression of extracellular matrix components in human heart valves. J Heart Valve Dis (2005) 1.36
Nano-analytical electron microscopy reveals fundamental insights into human cardiovascular tissue calcification. Nat Mater (2013) 1.34
On terminal alkynes that can react with active-site cysteine nucleophiles in proteases. J Am Chem Soc (2013) 1.32
Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun (2013) 1.31
Neglected tropical cardiomyopathies: II. Endomyocardial fibrosis: myocardial disease. Heart (2008) 1.29
Two novel ubiquitin-fold modifier 1 (Ufm1)-specific proteases, UfSP1 and UfSP2. J Biol Chem (2006) 1.26
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res (2006) 1.25
Revealing new mouse epicardial cell markers through transcriptomics. PLoS One (2010) 1.24
Adipose tissue: friend or foe? Nat Rev Cardiol (2012) 1.24
The structure and function of cardiac t-tubules in health and disease. Proc Biol Sci (2011) 1.23
Recombination-induced tag exchange to track old and new proteins. Proc Natl Acad Sci U S A (2009) 1.23
The triage of damaged proteins: degradation by the ubiquitin-proteasome pathway or repair by molecular chaperones. FASEB J (2006) 1.23
Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun (2007) 1.23
Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol Endocrinol (2012) 1.21
Bridge to recovery with the use of left ventricular assist device and clenbuterol. Ann Thorac Surg (2003) 1.17
Cytoskeletal protein 4.1R affects repolarization and regulates calcium handling in the heart. Circ Res (2008) 1.17
Inhibition of NF-κB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE. J Immunol (2010) 1.17
Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol Carcinog (2006) 1.17
Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis. J Immunol (2013) 1.16
Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends Pharmacol Sci (2005) 1.16
The effect of microgrooved culture substrates on calcium cycling of cardiac myocytes derived from human induced pluripotent stem cells. Biomaterials (2012) 1.16
Induction of the cytoprotective enzyme heme oxygenase-1 by statins is enhanced in vascular endothelium exposed to laminar shear stress and impaired by disturbed flow. J Biol Chem (2009) 1.16
Long-term outcomes of patients bridged to recovery versus patients bridged to transplantation. J Thorac Cardiovasc Surg (2012) 1.15
Genetic background affects function and intracellular calcium regulation of mouse hearts. Cardiovasc Res (2010) 1.15
Cardiac fibrosis in mice expressing an inducible myocardial-specific Cre driver. Dis Model Mech (2013) 1.15
Heat shock protein 72 enhances manganese superoxide dismutase activity during myocardial ischemia-reperfusion injury, associated with mitochondrial protection and apoptosis reduction. Circulation (2002) 1.15
Ubiquitin-specific protease-like 1 (USPL1) is a SUMO isopeptidase with essential, non-catalytic functions. EMBO Rep (2012) 1.15